Cirius Therapeutics, Inc.

While analysts were divided on whether there were broader implications for non-alcoholic steatohepatitis (NASH) R&D following the complete response letter that Intercept Pharmaceuticals Inc. reveale

One month after competitor Genfit SA crashed with a Phase III failure in NASH, Inventiva Pharma is moving toward the front of the pack in non-alcoholic steatohepatitis with Phase IIb data showing

Without an approved therapy to establish a treatment paradigm, the non-alcoholic steatohepatitis (NASH) market is still untested – leaving the cluttered research and development space with a mix of co

Cirius Therapeutics Inc. obtained mixed results in the Phase IIb dose-ranging study of its insulin-sensitizer MSDC-0602K in non-alcoholic steatohepatitis (NASH), but the privately held firm thinks it